Omnia Family Wealth LLC Buys 591 Shares of Pfizer Inc. (NYSE:PFE)

Omnia Family Wealth LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 8.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,008 shares of the biopharmaceutical company’s stock after acquiring an additional 591 shares during the period. Omnia Family Wealth LLC’s holdings in Pfizer were worth $232,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Olistico Wealth LLC purchased a new stake in shares of Pfizer during the 2nd quarter valued at approximately $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer in the 2nd quarter valued at $29,000. Quarry LP bought a new position in Pfizer during the 2nd quarter worth approximately $31,000. Financial Connections Group Inc. purchased a new stake in shares of Pfizer during the second quarter valued at approximately $34,000. Finally, ESL Trust Services LLC purchased a new position in shares of Pfizer in the first quarter worth $37,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on PFE. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Citigroup initiated coverage on Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective for the company. UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Finally, Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Stock Down 0.6 %

Shares of NYSE:PFE traded down $0.15 during trading on Thursday, reaching $26.57. 10,955,840 shares of the stock traded hands, compared to its average volume of 37,643,223. The stock has a 50-day moving average of $28.76 and a two-hundred day moving average of $28.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54. The stock has a market cap of $150.57 billion, a P/E ratio of 35.74, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the prior year, the company posted ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% on a year-over-year basis. As a group, sell-side analysts expect that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.32%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Insider Buying and Selling

In other news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.06% of the stock is currently owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.